Comparing the Top Two: Genomic Health, Inc. (NASDAQ:GHDX), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Genomic Health, Inc. (NASDAQ:GHDX)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) closed at $52.93 on the last trading session with an decrease of -1.51%, whereas, it previously closed at $53.74. The company has a market capitalization of $5.33 Billion. The company traded shares of 718533 on the trading day while its three month average volume stands at 711.7 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) produced diluted EPS of 0.9. The EPS estimate for next year as estimated by analysts is at -0.54 while EPS for next quarter is estimated at -0.01. Earnings per Share growth for this year is reported at 572.9, while the analysts estimated the EPS growth for next year at -0.54% and Earnings growth for next 5 years stands at 49% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 52.4%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is at 59.01 while the forward p/e is at 0. The P/S or Price to Sales ratio of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands at 5.67 and Price to Book or P/B for the most recent quarter stands at 5.36. The Price to Free Cash Flow ratio or P/FCF is reported at 31.07. The quick ratio and the current ratio of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) are reported at 10.8 and 10.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands at 4.2, 9.4 and 13.4 respectively

The trailing twelve month Revenue of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is reported at 940.5 Million with income of 130.5 Million. The outstanding shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) are 139.35 Million. The institutional Ownership of the shares of 87.93 stands at 0.80%, this figure is increased 2.86 in the last six months. The insider ownership for the shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is ticked at 0.4%, the figure is plummeted -25.04% in the last six months.

Some other important financial aspects to be discussed here for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is the Mean Target Price estimated by the analysts which stands at 68.06. The 52 week high of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is placed at 66.25 and 52 week low is standing at 39.32.

Performance wise the shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) rose up 0.4% for the week, it also rise 0.28% for the monthly performance, while for the quarter it went up -7.14%. The shares increase 18.94% for the half year and plummeted for the Year-To-Date performance. The shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shrinked -18.73% for the yearly performance.